Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8277343 | Journal of the Neurological Sciences | 2014 | 5 Pages |
Abstract
These results suggest that JGK-263, an oral GSK-3β inhibitor, is promising as a novel therapeutic agent for ALS. Still, further biochemical studies on the underlying mechanisms and safety of JGK-263 are necessary.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Suk-Won Ahn, Gye Sun Jeon, Myung-Jin Kim, Jee-Heun Shon, Jee-Eun Kim, Je-Young Shin, Sung-Min Kim, Seung Hyun Kim, In-Hae Ye, Kwang-Woo Lee, Yoon-Ho Hong, Jung-Joon Sung,